Published in PLoS Med on December 01, 2006
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood (2008) 2.87
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res (2009) 2.13
Mutational heterogeneity in human cancers: origin and consequences. Annu Rev Pathol (2010) 2.02
Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst (2010) 1.92
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res (2009) 1.80
Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 1.77
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther (2011) 1.74
Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med (2008) 1.70
Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) (2010) 1.66
DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer (2008) 1.55
Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene (2010) 1.52
Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47
Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res (2009) 1.44
Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene (2010) 1.36
DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med (2010) 1.32
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res (2012) 1.32
Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer (2010) 1.30
Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One (2007) 1.22
Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer (2011) 1.22
Hypomethylation of intragenic LINE-1 represses transcription in cancer cells through AGO2. PLoS One (2011) 1.18
DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS One (2011) 1.16
Genome-scale DNA methylation analysis. Epigenomics (2010) 1.15
A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer Res (2009) 1.14
Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br J Cancer (2011) 1.13
An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer. BMC Syst Biol (2010) 1.10
Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J (2009) 1.10
Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res (2010) 1.08
Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. J Cell Mol Med (2009) 1.03
Smoking-related genomic signatures in non-small cell lung cancer. Am J Respir Crit Care Med (2008) 1.03
Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. Mol Endocrinol (2012) 1.01
Genomic impact of cigarette smoke, with application to three smoking-related diseases. Crit Rev Toxicol (2012) 1.00
DNA methylation as clinically useful biomarkers-light at the end of the tunnel. Pharmaceuticals (Basel) (2012) 0.99
Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res (2013) 0.98
Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenetics Chromatin (2012) 0.98
TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med (2012) 0.97
Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med (2013) 0.96
DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Arch (2011) 0.94
Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4. Oncogene (2012) 0.94
Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res (2016) 0.94
The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development. Proc Natl Acad Sci U S A (2008) 0.93
Msx and dlx homeogene expression in epithelial odontogenic tumors. J Histochem Cytochem (2008) 0.93
Overexpression of LIM and SH3 Protein 1 leading to accelerated G2/M phase transition contributes to enhanced tumourigenesis in oral cancer. PLoS One (2013) 0.92
Do we use the appropriate controls for the identification of informative methylation markers for early cancer detection? Genome Biol (2008) 0.91
Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer Metastasis Rev (2010) 0.90
Lung cancer and its association with chronic obstructive pulmonary disease: update on nexus of epigenetics. Curr Opin Pulm Med (2011) 0.89
Mining the epigenome for methylated genes in lung cancer. Proc Am Thorac Soc (2008) 0.89
Lung cancer: a modified epigenome. Cell Adh Migr (2010) 0.89
Identification of methylation profile of HOX genes in extrahepatic cholangiocarcinoma. World J Gastroenterol (2011) 0.88
Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. PLoS One (2014) 0.88
DNA methylation in promoter region as biomarkers in prostate cancer. Methods Mol Biol (2012) 0.88
The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells. Mol Cell Biol (2011) 0.88
MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α. Mol Cancer (2016) 0.87
Lung cancer in never smokers: a call to action. Clin Cancer Res (2009) 0.87
Cyclin A1 regulates the interactions between mouse haematopoietic stem and progenitor cells and their niches. Cell Cycle (2015) 0.86
The lysyl oxidase propeptide interacts with the receptor-type protein tyrosine phosphatase kappa and inhibits β-catenin transcriptional activity in lung cancer cells. Mol Cell Biol (2011) 0.86
The significance of epigenetic alterations in lung carcinogenesis. Mol Biol Rep (2012) 0.86
Development of a multiplex methylation specific PCR suitable for (early) detection of non-small cell lung cancer. Epigenetics (2014) 0.86
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics (2014) 0.85
Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells. J Pharmacol Exp Ther (2013) 0.85
Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer. PLoS One (2013) 0.84
Surfactant protein DNA methylation: a new entrant in the field of lung cancer diagnostics? (Review). Oncol Rep (2009) 0.84
Lysyl oxidase: a potential target for cancer therapy. Inflammopharmacology (2010) 0.84
Mining methylation for early detection of common cancers. PLoS Med (2006) 0.84
Inferring combinatorial association logic networks in multimodal genome-wide screens. Bioinformatics (2010) 0.82
Comprehensive DNA Methylation Analysis Reveals a Common Ten-Gene Methylation Signature in Colorectal Adenomas and Carcinomas. PLoS One (2015) 0.82
Identification of differentially-expressed genes by DNA methylation in cervical cancer. Oncol Lett (2015) 0.82
Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide. PLoS One (2012) 0.81
The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. Clin Epigenetics (2015) 0.81
Methylation status of NEUROG2 and NID2 improves the diagnosis of stage I NSCLC. Oncol Lett (2012) 0.81
Methods for cancer epigenome analysis. Adv Exp Med Biol (2013) 0.80
Association between RUNX3 promoter methylation and non-small cell lung cancer: a meta-analysis. J Thorac Dis (2014) 0.78
A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. Ann Thorac Cardiovasc Surg (2009) 0.78
A prognostic predictor panel with DNA methylation biomarkers for early-stage lung adenocarcinoma in Asian and Caucasian populations. J Biomed Sci (2016) 0.77
An Integrated Analysis of the Genome-Wide Profiles of DNA Methylation and mRNA Expression Defining the Side Population of a Human Malignant Mesothelioma Cell Line. J Cancer (2016) 0.77
CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer. Cancer Biol Ther (2012) 0.77
Genetic and epigenetic marker-based DNA test of stool is a promising approach for colorectal cancer screening. Yonsei Med J (2009) 0.76
Genome Wide Methylome Alterations in Lung Cancer. PLoS One (2015) 0.75
Analysis of Microarray Data on Gene Expression and Methylation to Identify Long Non-coding RNAs in Non-small Cell Lung Cancer. Sci Rep (2016) 0.75
REGNET: mining context-specific human transcription networks using composite genomic information. BMC Genomics (2014) 0.75
Epigenetic regulations of inflammatory cyclooxygenase-derived prostanoids: molecular basis and pathophysiological consequences. Mediators Inflamm (2015) 0.75
Peperomin E reactivates silenced tumor suppressor genes in lung cancer cells by inhibition of DNA methyltransferase. Cancer Sci (2016) 0.75
Decreased Expression of BNC1 and BNC2 Is Associated with Genetic or Epigenetic Regulation in Hepatocellular Carcinoma. Int J Mol Sci (2016) 0.75
Modeling the Etiology of p53-mutated Cancer Cells. J Biol Chem (2016) 0.75
Regulation of retinoic acid synthetic enzymes by WT1 and HDAC inhibitors in 293 cells. Int J Mol Med (2017) 0.75
Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer. Onco Targets Ther (2017) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Molecular portraits of human breast tumours. Nature (2000) 94.14
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (2003) 52.74
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
p53 mutations in human cancers. Science (1991) 31.96
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet (2003) 25.57
High sensitivity mapping of methylated cytosines. Nucleic Acids Res (1994) 16.62
Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet (1999) 14.96
MethPrimer: designing primers for methylation PCRs. Bioinformatics (2002) 14.48
The history of cancer epigenetics. Nat Rev Cancer (2004) 14.38
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer (2006) 11.22
Empirical bayes methods and false discovery rates for microarrays. Genet Epidemiol (2002) 10.56
The epigenetic progenitor origin of human cancer. Nat Rev Genet (2006) 9.65
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
A gene hypermethylation profile of human cancer. Cancer Res (2001) 8.93
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics (2005) 5.95
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet (2006) 4.97
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res (2006) 3.45
NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl (1996) 3.24
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer (1998) 3.12
Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer (2004) 3.10
Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res (2001) 2.80
A systematic profile of DNA methylation in human cancer cell lines. Cancer Res (2003) 2.75
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs. Nat Chem Biol (2005) 2.34
DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res (2006) 2.29
Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res (2001) 2.18
Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell (2005) 2.17
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst (2004) 2.08
Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst (2005) 2.08
A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res (2004) 2.06
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res (2003) 2.03
Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res (2005) 1.93
Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res (2002) 1.74
Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res (2004) 1.74
CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res (2006) 1.49
Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res (2004) 1.35
Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res (2004) 1.35
Retracted Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers. Int J Cancer (2006) 1.25
Microsatellite instability and other molecular abnormalities in non-small cell lung cancer. Cancer Res (1995) 1.22
Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett (2006) 1.19
Gene-Ontology analysis reveals association of tissue-specific 5' CpG-island genes with development and embryogenesis. Hum Mol Genet (2004) 1.16
Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling. Clin Cancer Res (2005) 1.14
The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines. Oncogene (2002) 1.14
Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. Int J Cancer (2005) 1.11
Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. Cancer Res (1995) 1.05
Unanswered questions about the role of promoter methylation in carcinogenesis. Ann N Y Acad Sci (2003) 1.02
Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer. Cancer Res (1995) 1.00
Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res (2004) 0.96
Correlation of loss of heterozygosity at 11p with tumour progression and survival in non-small cell lung cancer. Genes Chromosomes Cancer (1994) 0.88
Human papillomavirus not found in squamous and large cell lung carcinomas by polymerase chain reaction. Cancer (1995) 0.78
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell (2002) 17.32
BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Evolutionary and biomedical insights from the rhesus macaque genome. Science (2007) 16.21
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med (2004) 9.81
MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
A custom microarray platform for analysis of microRNA gene expression. Nat Methods (2004) 9.44
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2008) 7.65
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res (2008) 7.39
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Molecular characterisation of soft tissue tumours: a gene expression study. Lancet (2002) 7.05
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
Lung cancer in never smokers--a different disease. Nat Rev Cancer (2007) 6.41
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A (2007) 5.95
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer (2006) 5.39
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Deconstructing the molecular portraits of breast cancer. Mol Oncol (2010) 5.37
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
Adjustment of systematic microarray data biases. Bioinformatics (2004) 5.22
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst (2003) 5.09
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol (2006) 4.49
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology (2009) 4.08
Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet (2003) 4.01
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98